GO
Loading...

Sanofi CEO: Alnylam deal extension of Genzyme philosophy

Monday, 13 Jan 2014 | 10:10 AM ET

Chris Viehbacher, Sanofi CEO, discusses the $700 million deal Sanofi struck with Alnylam and the company's growth into the treatment of genetic diseases.